Successfully Commenced Larger Animal Studies for Lead Program VP-001 for Treatment of Retinitis Pigmentosa Type 11 with Key Data Readouts in Two Species Expected in 2H 2021; On-track For Investigational New Drug Application in Mid-2022
Second Lead Program VP-002 for Treatment of Autosomal Dominant Optic Atrophy Achieved Effective Delivery to Target Cells in the Retina In Vivo, Upregulation of Target OPA1 Protein and Correction of Major Functional Deficits in Patient-Derived Cells
PPMO Technology Successfully Delivered High Levels of RNA Therapeutic Throughout Mouse Brain in First Preclinical Results for Central Nervous System Program; Company to Nominate First CNS Development Candidate in 2H 2021
PR Newswire
SAN DIEGO and PERTH, Australia, July 28, 2021
